Zacks Research Upgrades Plus Therapeutics (NASDAQ:CNSY) to “Hold”

Plus Therapeutics (NASDAQ:CNSY) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Tuesday, Zacks reports.

Separately, Weiss Ratings assumed coverage on Plus Therapeutics in a report on Tuesday, August 4th. They set a “sell (e+)” rating on the stock. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce”.

Plus Therapeutics Trading Up 8.5%

Shares of NASDAQ CNSY opened at $2.94 on Tuesday. Plus Therapeutics has a 12-month low of $2.62 and a 12-month high of $23.42. The stock has a market capitalization of $22.31 million, a price-to-earnings ratio of -0.88 and a beta of 1.39.

Plus Therapeutics (NASDAQ:CNSY) last issued its quarterly earnings data on Friday, August 14th. The company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.35). Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%. On average, equities analysts predict that Plus Therapeutics will post -3.76 EPS for the current fiscal year.

About Plus Therapeutics

Plus Therapeutics, Inc is a clinical-stage pharmaceutical company focused on developing targeted radiotherapeutics for difficult-to-treat cancers. The company’s technology is designed to deliver radioactive payloads directly to tumors, with the goal of improving local treatment while limiting exposure to surrounding healthy tissue.

Its lead investigational product is rhenium-186 nanoliposomes, also known as 186RNL, a nanotechnology-based radiotherapeutic being evaluated for recurrent glioblastoma and leptomeningeal metastases.